이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM) (CYC-ADEM-Peds)

2026년 11월 15일 업데이트: Damascus University

A Randomized, Open-Label, Comparative Clinical Trial Evaluating the Efficacy and Safety of Cyclophosphamide Versus Intravenous Immunoglobulin (IVIG) in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis

Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.

This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.

연구 개요

상세 설명

Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.

This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.

Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).

Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Damascus, 시리아
        • 모병
        • Children's University Hospital
        • 연락하다:
        • 수석 연구원:
          • Fatima Amer, MD
        • 수석 연구원:
          • Sameer Baqla, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

13년 이하 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Pediatric patients younger than 14 years of age (< 14 years) at clinical presentation.
  • Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
  • Steroid-refractory clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
  • Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
  • Intact baseline hepatic function (AST, ALT, and bilirubin within acceptable limits).
  • Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
  • Formal written informed consent obtained from parents or legal guardians.

Exclusion Criteria:

  • Patients aged 14 years and older (≥ 14.0 years).
  • Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
  • Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
  • Active systemic sepsis or uncontrolled severe systemic infection.
  • Pre-existing severe bone marrow suppression (baseline absolute neutrophil count ANC ≤ 1500/mm³ or platelet count < 50,000/mm³).
  • History of known hypersensitivity to cyclophosphamide, Mesna, or immunoglobulin preparations.
  • Alternative neuroinflammatory or metabolic diagnosis confirmed.
  • Refusal of parents or legal guardians to grant written informed consent.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cyclophosphamide IV

Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment.

Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis.

활성 비교기: Intravenous Immunoglobulin (IVIG)

Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM.

Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)
기간: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.

Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories:

  • Score 5: Full recovery (resumed normal activities / baseline abilities)
  • Score 4: Minor sequelae (mild behavioral changes or mild motor deficits with full independence)
  • Score 3: Moderate sequelae (independent in basic daily self-care but impaired in higher tasks)
  • Score 2: Major sequelae (severe physical or cognitive impairment, dependent on caregivers)
  • Score 1: Death
Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.

2차 결과 측정

결과 측정
측정값 설명
기간
Radiological Resolution on Neuroimaging (Brain & Spine MRI)
기간: Assessed at 2,4 and 12 weeks post-treatment initiation.

Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions.

Assessed at 2,4 and 12 weeks post-treatment initiation.
Overall Survival and All-Cause Mortality Rate
기간: Up to 24 months

Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window.

Up to 24 months
Treatment-Emergent Adverse Events & Tolerability
기간: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.

Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis)

Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Fatima Amer, MD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
  • 연구 책임자: Sameer Baqla, PhD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
  • 연구 책임자: Sally Kadoura, PhD, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 17일

기본 완료 (추정된)

2027년 2월 17일

연구 완료 (추정된)

2027년 3월 17일

연구 등록 날짜

최초 제출

2026년 11월 15일

QC 기준을 충족하는 최초 제출

2026년 11월 15일

처음 게시됨 (실제)

2026년 11월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 15일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다